Niels W.C.J. van de Donk
A5032546995- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Cancer Treatment and Pharmacology
- Immune Cell Function and Interaction
- Synthesis and Biological Evaluation
- Immunotherapy and Immune Responses
- Cancer therapeutics and mechanisms
- Biosimilars and Bioanalytical Methods
- T-cell and B-cell Immunology
- Ubiquitin and proteasome pathways
- Calcium signaling and nucleotide metabolism
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Histone Deacetylase Inhibitors Research
- Extracellular vesicles in disease
- Glycosylation and Glycoproteins Research
- Quinazolinone synthesis and applications
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chemokine receptors and signaling
- Cancer Mechanisms and Therapy
- Lymphoma Diagnosis and Treatment
- Viral Infectious Diseases and Gene Expression in Insects
Vrije Universiteit Amsterdam
2017-2025
Amsterdam University Medical Centers
2004-2025
Cancer Center Amsterdam
2018-2024
Amsterdam UMC Location Vrije Universiteit Amsterdam
2014-2024
University of Amsterdam
2023-2024
Dutch Cancer Society
2024
BD Biosciences (United States)
2024
Janssen (United States)
2023
University of Oxford
2023
NYU Langone Health
2023
Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeting, human IgG1κ monoclonal antibody, in phase 1-2 trial involving patients with relapsed or that was refractory to two more prior lines of therapy.In part 1, the dose-escalation phase, we administered daratumumab at doses 0.005 24 mg per kilogram body weight. In 2, dose-expansion 30 received 8 and 42 16 kilogram, once weekly (8 doses), twice monthly for up months. End points included safety, efficacy,...
Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen myeloma cells. In phase 1 dose-defining portion study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.
G protein-coupled receptor, family C, group 5, member D (GPRC5D) is an orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody against CD3 and GPRC5D, redirects T cells to mediate killing of GPRC5D-expressing myeloma cells.In phase 1 study, we evaluated talquetamab administered intravenously weekly or every other week (in doses from 0.5 180 μg per kilogram body weight) subcutaneously weekly, week, monthly (5 1600 kilogram) patients who had heavily pretreated...
Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel earlier treatment lines lenalidomide-refractory disease. Download PDF of the Research Summary. In this phase 3, randomized, open-label trial, we assigned myeloma to receive physician's choice standard care. All had received one three previous treatment. The primary outcome was...
The European Myeloma Network provides recommendations for the management of most common complications multiple myeloma. Whole body low-dose computed tomography is more sensitive than conventional radiography in depicting osteolytic disease and thus we recommend it as novel standard detection lytic lesions myeloma (grade 1A). patients with adequate renal function bone at diagnosis should be treated zoledronic acid or pamidronate Symptomatic without on can 1B), but its advantage not clear no...
PURPOSE Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the Revised International Staging system (R-ISS), standard-of-care risk stratification model. Moreover, chromosome 1q gain/amplification (1q+) recently proved be a poor prognostic factor. In this study, we revised R-ISS by analyzing additive value each single feature, including 1q+. PATIENTS AND METHODS The European Myeloma Network,...
Daratumumab is an anti-CD38 monoclonal antibody with lytic activity against multiple myeloma (MM) cells, including ADCC (antibody-dependent cellular cytotoxicity) and CDC (complement-dependent cytotoxicity). Owing to a marked heterogeneity of response daratumumab therapy in MM, we investigated determinants the sensitivity MM cells toward daratumumab-mediated CDC. In bone marrow samples from 144 patients, observed no difference lysis between newly diagnosed or relapsed/refractory patients....
Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined bortezomib, lenalidomide, and dexamethasone (VRd) the treatment transplantation-eligible patients newly diagnosed multiple is needed. Download PDF Research Summary. In this phase 3 trial, we randomly assigned 709 to receive either VRd induction consolidation therapy lenalidomide maintenance (D-VRd group) or alone (VRd group). The...
Multiple myeloma management has undergone profound changes in the past thanks to advances our understanding of disease biology and improvements treatment supportive care approaches. This article presents recommendations European Myeloma Network for newly diagnosed patients based on GRADE system level evidence. All with symptomatic should undergo risk stratification classify International Staging System stage (level evidence: 1A) cytogenetically defined high- versus standard-risk groups (2B)....
Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life care (SOC) in triple-class exposed (received at least a PI, IMiD, mAb) relapsed/refractory MM (RRMM). Patients (N = 248; ECOG performance status 0-1, ≥3 prior lines...